|1.||Ruggiero, Vito: 3 articles (01/2011 - 06/2004)|
|2.||Yang, Bo: 3 articles (01/2006 - 10/2003)|
|3.||D'Alessio, Valeria: 2 articles (01/2011 - 07/2008)|
|4.||Rossi, Stefania: 2 articles (01/2011 - 07/2008)|
|5.||De Santis, Rita: 2 articles (01/2011 - 07/2008)|
|6.||Campo, Silvia: 2 articles (01/2011 - 07/2008)|
|7.||Arseni, Brunilde: 2 articles (01/2011 - 07/2008)|
|8.||Carminati, Paolo: 2 articles (07/2008 - 06/2004)|
|9.||Fang, Rui-ying: 2 articles (01/2006 - 10/2003)|
|10.||He, Qiao-jun: 2 articles (01/2006 - 10/2003)|
01/01/2011 - "Previous studies demonstrated that ST1959, a triazole derivative endowed with immunomodulatory activities, also exerts inhibitory effects on proliferation and survival of a panel of tumor cells. "
01/01/2006 - "DL111-IT could inhibit the proliferation of cancer cells both in vitro and in vivo via a cell cycle regulation pathway."
01/01/2006 - "DL111-IT exhibited high efficiency on cell growth inhibition of 12 cancer cell lines, the IC50 values were 4.1-19.7 microg/ml. In Sarcoma-180 (S180) and Hepatoma-22 (H22) tumor bearing mice models, the inhibition rates were 55.9 and 55.6%, respectively, at the doses of DL111-IT 12.5-50.0 mg/kg for 9 days consecutive administration. "
01/01/2006 - "Antiproliferative activity of contragestazol (DL111-IT) in murine and human tumor models in vitro and in vivo."
12/01/2005 - "The drug concentration that yielded 50% cell inhibition (IC50 value) was 9.9 mg/mL. In the PC3 tumor xenograft study, DL111-IT (1.25 mg/kg-20.0 mg/kg) given once a day for 10 days significantly inhibited tumor growth, with the inhibition rate ranging from 21% to 50%. "
|3.||Prostatic Neoplasms (Prostate Cancer)
01/01/2011 - "In this study, we sought to ascertain the effects of ST1959 on the growth of androgen-dependent and androgen-independent prostate cancer (PCa) cells. "
12/01/2005 - "DL111-IT inhibits the proliferation of human androgen-independent prostate cancer cell line PC3 in vitro and in vivo by a cell cycle regulation pathway."
12/01/2005 - "DL111-IT exhibited high efficiency on cell growth inhibition of the human androgen-independent prostate cancer cell line PC3. "
12/01/2005 - "To evaluate the antiproliferative activity of contragestazol (DL111-IT) on the human prostate cancer cell line PC3 in vitro and in vivo and to elucidate its potential molecular mechanisms. "
12/01/2005 - "Contragestazol (DL111-IT) inhibits proliferation of human androgen-independent prostate cancer cell line PC3 in vitro and in vivo."
|1.||3- (2- ethylphenyl)- 5- (3- methoxyphenyl)- 1H- 1,2,4- triazole
|2.||Mifepristone (RU 486)
|8.||Androgen Receptors (Androgen Receptor)
|10.||Interferon-gamma (Interferon, gamma)
|1.||Heterologous Transplantation (Xenotransplantation)